RT Journal Article SR Electronic T1 The Clinical Influence of the C-Reactive Protein-to-Albumin Ratio in Patients Who Received Curative Treatment for Gastric Cancer JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 3475 OP 3482 DO 10.21873/invivo.12648 VO 35 IS 6 A1 TORU AOYAMA A1 MASATO NAKAZONO A1 KENKI SEGAMI A1 SHINSUKE NAGASAWA A1 KAZUKI KANO A1 TAKANOBU YAMADA A1 YUKIO MAEZAWA A1 KENTARO HARA A1 ITARU HASHIMOTO A1 HIDEAKI SUEMATSU A1 HAYATO WATANABE A1 KOSUKE TAKAHASHI A1 MASAKATSU NUMATA A1 HIROSHI TAMAGAWA A1 NORIO YUKAWA A1 YASUSHI RINO A1 TAKASHI OGATA A1 TAKASHI OSHIMA YR 2021 UL http://iv.iiarjournals.org/content/35/6/3475.abstract AB Background: We investigated the impact of the pre-surgical C-reactive protein-to-albumin ratio (CAR) on survival and recurrence after curative treatment for gastric cancer. Patients and Methods: This study included 481 patients who underwent curative treatment for gastric cancer between 2013 and 2017. The risk factors for overall (OS) and recurrence-free (RFS) survival were identified. Results: A CAR of 0.05 was regarded as the optimal critical point of classification considering the 3- and 5-year survival rates and patients were divided according to their CAR. The OS rates at 3 and 5 years after surgery were significantly higher at 92.5% and 87.9%, respectively, in the low-CAR group compared with 84.9% and 71.9%, respectively, in the high-CAR group. The corresponding RFS rates were 89.1% and 85.5%, and 81.0% and 72.2%, respectively, also a significant difference. A multivariate analysis demonstrated that the CAR was a significant independent risk factor for the OS and marginally significant independent risk factor for the RFS. In addition, the incidences of pancreatic fistula and abdominal abscess were significantly higher and the rate of introduction of adjuvant chemotherapy significantly lower in the high-CAR group. Conclusion: The CAR was a risk factor influencing survival in patients who underwent curative treatment for gastric cancer. An effective perioperative care plan and surgical strategy need to be developed according to the CAR.